AION Healthspan, Inc. is conducting a clinical trial at the University of Miami Health System to evaluate the safety of REJUVXL, a novel cell therapy given through a simple IV infusion (similar to a blood transfusion) that does not require any anti-rejection drug. The objective of the clinical trial is to slow down, or possibly even reverse, Chronic Kidney Disease (CKD; Stage 3), with the goal of preventing progression to dialysis and kidney transplantation.
Why This Study Matters
- Chronic Kidney Disease affects hundreds of millions
- 1 in 3 adults with diabetes develops CKD
- Nearly 40% of people over 65 are affected
- Current treatments can only slow CKD progression towards dialysis and kidney transplantation
What is REJUVXL?
REJUVXL is an innovative cell therapeutic strategy developed to:
- Reduce inflammation in the kidneys
- Repair and regenerate damaged tissue
- Improve kidney function
- Slow or stop CKD progression
Who Can Participate?
You may qualify if you:
- Have been diagnosed with Stage 3 Chronic Kidney Disease
Participants will receive:
- Study-related medical care
- Close monitoring by leading kidney specialists
- A stipend will be provided for transportation costs and meals, to attend each onsite visit
- An opportunity to help advance CKD treatment for the future
Interested in Participating?
- Find out if you qualify today!
- Contact: Dr. Danay Saavedra Hernandez
- Email: dxs4415@med.miami.edu
- Tel: (305) 243-6616
Sign up for news to stay up to date on our clinical trial plans